Frequent Inactivation of <i>Cysteine Dioxygenase Type 1</i> Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines

Abstract

We report that silencing of CDO1 is a critical epigenetic event that contributes to the survival of oxidative-stressed breast cancer cells through increased detoxification of ROS and thus leads to the resistance to ROS-generating chemotherapeutics including anthracyclines. Our study shows the importance of CDO1 inactivation in breast cancer and its clinical potential as a biomarker and therapeutic target to overcome resistance to anthracyclines.